Obesity drug coverage slips
- Insurers cut coverage sharply, leaving many patients to stop their GLP-1 obesity drugs or seek alternatives. (npr.org) - NPR reports roughly 12 million people lost coverage for Zepbound and another 12 million lost Wegovy coverage in 2025–2026. (npr.org) - Patients are switching meds or compounding options, while analysts say a delayed Medicare pilot likely won’t curb near-term demand. (wxxinews.org)
Health plans are dropping or tightening coverage for blockbuster obesity drugs, pushing many patients off Zepbound and Wegovy in 2025 and 2026. (wxxinews.org) GoodRx, using formulary data that reflects coverage for more than 190 million people, found 12 million people lost Zepbound coverage over the last year and another 12 million lost Wegovy coverage. The same analysis found that among people who still have coverage, 88% face at least one restriction such as prior authorization or a body mass index threshold. (wxxinews.org) Those restrictions are showing up in employer and commercial insurance plans, where insurers and self-funded companies decide each year which drugs stay on the formulary, the covered-drug list. Patients interviewed by NPR said they switched medicines, stretched doses, or looked for cheaper compounded versions after plans changed. (wxxinews.org) These drugs are glucagon-like peptide-1 medicines, or GLP-1s, which mimic gut hormones that reduce appetite and slow digestion. Doctors prescribe them for obesity as long-term treatment, not a short course, and NPR reported many patients who stop because of cost or coverage regain weight. (npr.org) Coverage has become the pressure point because demand rose faster than many employers and insurers expected, while list prices stayed high. NPR previously reported that employers were already struggling with whether to keep paying for medicines like Wegovy as use spread beyond diabetes care into obesity treatment. (npr.org) The fallback options are also getting narrower. NPR reported in March 2025 that compounding pharmacies had to stop making cheaper copies of Zepbound as shortage-related exceptions expired, leaving many patients scrambling for substitutes. (wxxinews.org) Some online sellers and telehealth companies kept marketing obesity-drug alternatives after those deadlines, and NPR reported in June 2025 that several firms shifted to new arrangements or altered formulations to stay in the market. That gave patients another path outside insurance, but not necessarily a low-cost or stable one. (wxxinews.org) Federal policy is moving more slowly than the private market. CMS says its Medicare GLP-1 Bridge will give eligible Medicare Part D beneficiaries access to certain GLP-1 drugs from July 1, 2026, through December 31, 2027, after earlier plans for a broader pilot slipped. (cms.gov) Analysts told Reuters the Medicare delay is unlikely to dent near-term demand, because the biggest coverage fights are still happening in commercial insurance and employer plans right now. For patients already taking the drugs, the immediate question is less whether the medicines work than whether their plan will still pay for them next month. (usnews.com)
